Filter
81
Filtered Results: 81
Text search:
Pharmacy
Board
of
Australia
Featured
Recommendations
3
New Publications
19
Language
Document type
No document type
32
Studies & Reports
25
Manuals
9
Guidelines
9
Strategic & Response Plan
3
Training Material
2
Fact sheets
1
Countries / Regions
Kenya
5
Indonesia
4
South Africa
3
Global
3
Nigeria
2
Uganda
2
Philippines
2
Germany
2
Cambodia
2
Bangladesh
2
Brazil
2
Portugal
2
Liberia
1
Ethiopia
1
Zimbabwe
1
India
1
Nepal
1
Turkey
1
Thailand
1
Mozambique
1
Sudan
1
Namibia
1
Botswana
1
Angola
1
Myanmar / Burma
1
South–East Asia Region
1
Latin America and the Carribbean
1
Eastern Europe and Central Asia
1
Western and Central Europe
1
Africa
1
Qatar
1
Australia
1
Vietnam
1
France
1
United Kingdom
1
Spain
1
Authors & Publishers
Publication Years
Category
Countries
30
Public Health
7
Clinical Guidelines
2
Key Resources
2
Pharmacy & Technologies
2
Capacity Building
1
Toolboxes
Pharmacy
16
HIV
8
Mental Health
6
Global Health Education
4
AMR
4
Caregiver
4
NCDs
4
Disability
3
COVID-19
3
TB
2
Planetary Health
2
Rapid Response
1
Refugee
1
English version - This handbook sets out a the new paradigm for pharmacy practice. Its aim is to guide pharmacy educators in pharmacy practice, to ...
First Revised Edition
March 2000
Community pharmacists are the health professionals most accessible to the public and are a cornerstone of primary health care. The role of community pharmacists is expanding globally. This report pr...
The Pharmacovigilance team in WHO aims to assure the safety of medicines and vaccines by ensuring reliable and timely exchange of information on safety issues, promoting pharmacovigilance activities...
A global call to action to protect the mental health of health and care workers
DHS Further Analysis Reports No. 100
Myanmar is one of the world’s 22 high tuberculosis (TB) burden countries, and supporting TB control in Myanmar is a global priority. This report reflects the findings, discussions, conclusions and recommendations ... the fourth international review mission of the Myanmar National TB Programme (NTP), which brought together international and national partners to review progress in TB control and to offer guidance on future TB control directions and efforts.
A high-quality national disease prevalence survey completed in 2010 demonstrated a TB disease burden two to three times higher than anticipated on the basis of previous surveys. In 2011 about 200 000 adults and children will have developed TB, including 20 000 HIV infected and 9000 suffering from MDR-TB, both of which will require additional care and costly treatment. TB remains among the top killers of adults, and more women die of TB than from maternal causes.
A high-quality national disease prevalence survey completed in 2010 demonstrated a TB disease burden two to three times higher than anticipated on the basis of previous surveys. In 2011 about 200 000 adults and children will have developed TB, including 20 000 HIV infected and 9000 suffering from MDR-TB, both of which will require additional care and costly treatment. TB remains among the top killers of adults, and more women die of TB than from maternal causes.
Lancet Public health 2022 January 6, 2022 https://doi.org/10.1016/ S2468-2667(21)00249-8
Growth in the number of individuals living with dementia underscores the need for public health planning efforts and policy to address the needs ... this group. Country-level estimates can be used to inform national planning efforts and decisions. Multifaceted approaches, including scaling up interventions to address modifiable risk factors and investing in research on biological mechanisms, will be key in addressing the expected increases in the number of individuals affected by dementia.
Report of the 23rd WHO Expert Committee on the selection and use of essential medicines
This executive summary reports the recommendations made by the Expert Committee for the 2021 update ... the WHO Model List of Essential Medicines (EML) and the Model List of Essential Medicine for Children (EMLc).
The 23rd meeting of the WHO Expert Committee on Selection and Use of Essential Medicines was coordinated from Geneva, Switzerland, and held virtually from 21 June to 2 July 2021. The Committee considered 88 applications proposing additions, changes and deletions of medicines, medicine classes and formulation on the Model Lists of Essential Medicines. The Committee evaluated the scientific evidence for comparative effectiveness, safety and cost-effectiveness of the medicines in question. The Committee also considered a review of the therapeutic alternatives for medicines on the Model Lists, and update to the AWaRe classification of antibiotics, and reviews and reports relevant to the selection and use of essential medicines.
A systematic analysis for the Global Burden of Disease Study 2019. The Lancet Vol.399 Issue 10341 p.2129-2154
Human resources for health (HRH) include a range of occupations that aim to promote or...
